Study of Iptacopan for adults with PNH in China
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with PNH (a type of blood disorder)
- You have not had any previous treatments like eculizumab or ravulizumab (for one group), or you have been on them for at least 3 months (for another group)
- You are starting iptacopan therapy within 60 days of agreeing to join
- You have had vaccinations against meningitis and pneumonia at least 2 weeks before starting iptacopan (or you will take antibiotics if needed)
- You are not pregnant, breastfeeding, or planning to get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a follow-up for people who already finished the earlier phase 2 trial of the study drug LP-005 for PNH. The goal is to see if it's safe and effective for long-term treatment.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial tests an investigational drug called NM8074 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been treated with complement inhibitors. The goal is to see if NM8074 can reduce red blood cell destruction and improve anemia, potentially reducing the need for blood transfusions.
This program gives adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition, access to danicopan, an investigational pill that may help improve anemia. It is for people who have been on Soliris or Ultomiris for at least 6 months and still have significant anemia.
This trial tests an oral medication, iptacopan, for children with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. It aims to see how well the drug works in kids who have not tried anti-C5 therapy or who are switching from it.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.